journal article·2023-12-27

Anti-Inflammatory Artificial Extracellular Vesicles with Notable Inhibition of Particulate Matter-Induced Skin Inflammation and Barrier Function Impairment

Simon Park, Jaesung Lim, Seulgi Kim, Minha Jeon, Hwira Baek, Wooram Park, Juwon Park, Se−Na Kim, Nae-Gyu Kang, Chun Gwon Park, Jin Woong Kim

ACS Applied Materials & Interfaces· Volume 15· Issue 51
Publisher page

Abstract

Particulate matter (PM) exposure disrupts the skin barrier, causing cutaneous inflammation that may eventually contribute to the development of various skin diseases. Herein, we introduce anti-inflammatory artificial extracellular vesicles (AEVs) fabricated through cell extrusion using the biosurfactant PEGylated mannosylerythritol lipid (P-MEL), hereafter named AEV P-MEL . The P-MEL has anti-inflammatory abilities with demonstrated efficacy in inhibiting the secretion of pro-inflammatory mediators. Mechanistically, AEV P-MEL enhanced anti-inflammatory response by inhibiting the mitogen-activated protein kinase (MAPK) pathway and decreasing the release of inflammatory mediators such as reactive oxygen species (ROS), cyclooxygenase-2 (COX-2), and pro-inflammatory cytokines in human keratinocytes. Moreover, AEV P-MEL promoted increased expression levels of skin barrier proteins (e.g., involucrin, IVL) and water–proteins (e.g., aquaporin 3, AQP3). In vivo studies revealed that repeated PM exposure to intact skin resulted in cutaneous inflammatory responses, including increased skin thickness (hyperkeratosis) and mast cell infiltration. Importantly, our data showed that the AEV P-MEL treatment significantly restored immune homeostasis in the skin affected by PM-induced inflammation and enhanced the intrinsic skin barrier function. This study highlights the potential of the AEV P-MEL in promoting skin health against PM exposure and its promising implications for the prevention and treatment of PM-related skin disorders.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Air Quality and Health Impacts · Extracellular vesicles in disease · Heme Oxygenase-1 and Carbon Monoxide

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea

Department of Biomedical Engineering, SKKU Institute for Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea

Department of Intelligent Precision Healthcare Convergence, SKKU Institute for Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea

Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon 16419, Republic of Korea

Department of Tropical Medicine, Medical Microbiology, and Pharmacology, John A. Burns School Medicine, University of Hawai’i at Manoa, Honolulu 96813, United States

Research and Development Center, MediArk Inc.,Cheongju 28644, Republic of Korea

Department of Industrial Cosmetic Science, College of Bio-Health University System, Chungbuk National University, Cheongju 28644, Republic of Korea

R&D Campus, LG Household & Health Care, Seoul 07795, Republic of Korea

Funding

Korea Health Industry Development Institute · National Research Foundation of Korea · LG H&H Future Cosmetics Support Foundation (LG FCSF) · Korean Fund for Regenerative Medicine

References (59)

Show source-provided references
1. 10.1038/s41586-020-2902-810.1038/s41586-020-2902-8 ↗
2. 10.1073/pnas.180322211510.1073/pnas.1803222115 ↗
3. 10.1073/pnas.190503011610.1073/pnas.1905030116 ↗
4. 10.1177/175342591769986410.1177/1753425917699864 ↗
5. 10.1073/pnas.181610211610.1073/pnas.1816102116 ↗
6. 10.1016/j.coi.2020.02.00710.1016/j.coi.2020.02.007 ↗
7. 10.1038/jid.2013.51710.1038/jid.2013.517 ↗
8. 10.1016/j.clindermatol.2011.08.02210.1016/j.clindermatol.2011.08.022 ↗
9. 10.1007/s00204-018-2197-910.1007/s00204-018-2197-9 ↗
10. 10.1093/toxsci/kfv23010.1093/toxsci/kfv230 ↗
11. 10.1172/jci.insight.14518510.1172/jci.insight.145185 ↗
12. 10.1186/s12989-020-00366-y10.1186/s12989-020-00366-y ↗
13. 10.2147/IJN.S10906210.2147/IJN.S109062 ↗
14. 10.1186/s12989-020-00366-y10.1186/s12989-020-00366-y ↗
15. 10.3390/ijerph1009388610.3390/ijerph10093886 ↗
16. 10.1016/j.jdermsci.2018.04.01510.1016/j.jdermsci.2018.04.015 ↗
17. 10.21037/jtd.2017.09.13510.21037/jtd.2017.09.135 ↗
18. 10.1007/s10753-018-0910-810.1007/s10753-018-0910-8 ↗
19. 10.3390/cells906137810.3390/cells9061378 ↗
20. 10.1016/j.jgr.2021.05.00110.1016/j.jgr.2021.05.001 ↗
21. 10.2147/CCID.S12943710.2147/CCID.S129437 ↗
22. 10.1111/dth.1496010.1111/dth.14960 ↗
23. 10.1016/j.biopha.2021.11153410.1016/j.biopha.2021.111534 ↗
24. 10.1097/MOT.000000000000070110.1097/MOT.0000000000000701 ↗
25. 10.2174/138161282566619030615331810.2174/1381612825666190306153318 ↗
26. 10.1093/pcmedi/pbaa00710.1093/pcmedi/pbaa007 ↗
27. 10.1038/s41598-020-58909-410.1038/s41598-020-58909-4 ↗
28. 10.1016/j.omtm.2018.12.00310.1016/j.omtm.2018.12.003 ↗
29. 10.1038/s41598-020-57497-710.1038/s41598-020-57497-7 ↗
30. 10.1038/s41596-020-00466-110.1038/s41596-020-00466-1 ↗
31. 10.1038/s12276-019-0223-510.1038/s12276-019-0223-5 ↗
32. 10.1016/j.apsb.2016.02.00110.1016/j.apsb.2016.02.001 ↗
33. 10.1007/s10295-008-0460-410.1007/s10295-008-0460-4 ↗
34. 10.1021/acs.biomac.8b0029210.1021/acs.biomac.8b00292 ↗
35. 10.1039/D2NR04272J10.1039/D2NR04272J ↗
36. 10.1016/j.jiec.2023.02.01510.1016/j.jiec.2023.02.015 ↗
37. 10.1038/s41427-021-00287-y10.1038/s41427-021-00287-y ↗
38. 10.1021/nn402232g10.1021/nn402232g ↗
39. 10.3402/jev.v3.2464110.3402/jev.v3.24641 ↗
40. 10.3389/fimmu.2018.0073810.3389/fimmu.2018.00738 ↗
41. 10.1038/sj.cr.729010510.1038/sj.cr.7290105 ↗
42. 10.1167/iovs.10-667310.1167/iovs.10-6673 ↗
43. 10.3390/genes402010110.3390/genes4020101 ↗
44. 10.1128/MMBR.00031-1010.1128/MMBR.00031-10 ↗
45. 10.1016/j.jid.2020.03.97110.1016/j.jid.2020.03.971 ↗
46. 10.1016/j.jdermsci.2015.01.01110.1016/j.jdermsci.2015.01.011 ↗
47. 10.1089/ars.2019.801510.1089/ars.2019.8015 ↗
48. 10.1093/mutage/gez00410.1093/mutage/gez004 ↗
49. 10.7554/eLife.4844810.7554/eLife.48448 ↗
50. 10.5021/ad.2020.32.6.49610.5021/ad.2020.32.6.496 ↗
51. 10.1016/j.jdermsci.2006.06.00310.1016/j.jdermsci.2006.06.003 ↗
52. 10.1016/j.jep.2018.09.02510.1016/j.jep.2018.09.025 ↗
53. 10.1038/s41598-022-11553-610.1038/s41598-022-11553-6 ↗
54. 10.1016/j.ecoenv.2022.11363210.1016/j.ecoenv.2022.113632 ↗
55. 10.1016/j.jdermsci.2021.02.00410.1016/j.jdermsci.2021.02.004 ↗
56. Conti P. · Allergy. Asthma. Proc. · 2002 · 23 · 331
57. 10.1016/j.jaci.2015.09.05910.1016/j.jaci.2015.09.059 ↗
58. 10.1016/j.cellsig.2019.01.01010.1016/j.cellsig.2019.01.010 ↗
59. 10.1016/j.ijpharm.2019.05.01410.1016/j.ijpharm.2019.05.014 ↗